TRAUMA HELP: Healing and Analgesia With Propranolol (TRAUMA_HELP)
Phase IIB Study: TRAUMA HELP: Healing and Analgesia With Propranolol
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina Trauma Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- at least one fracture
- ages 18-60 yrs
- pain score >= 4
- speak and read English
Exclusion Criteria:
- gunshot, stab wound, or assault
- paraplegia/quadriplegia
- pregnancy
- psychotic, suicidal, or homicidal
- hepatic, kidney failure
- clinically unstable or intubated at time of recruitment
- hyperthyroidism
- propranolol use within the last 6 months
- significant bradycardia
- cancer (except basal cell)
- peripheral vascular disease
- heart block > 1 degree
- breastfeeding
- congestive heart failure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
PLACEBO_COMPARATOR: Sugar pill
|
sugar pill
Other Names:
|
|
EXPERIMENTAL: Propranolol
|
40 mg
Other Names:
120 mg twice per day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Daily average pain score (0-10 numeric rating pain score recorded daily from patient) after study drug initiation.
Time Frame: Study days 1, 3, 5, 7, 10, 13, 17, and 19
|
Study days 1, 3, 5, 7, 10, 13, 17, and 19
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Sleep quality
Time Frame: MOS Sleep Scale
|
MOS Sleep Scale
|
|
Anxiety symptoms
Time Frame: 7 days, 6 weeks, 3 months, 6 months
|
7 days, 6 weeks, 3 months, 6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Samuel M McLean, MD MPH, UNC Chapel Hill School of Medicine
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 09-1391
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.